{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:50:59Z","timestamp":1775065859450,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,11,7]],"date-time":"2003-11-07T00:00:00Z","timestamp":1068163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Imatinib mesylate is a specific inhibitor of protein tyrosine kinase activity secondary to bcr\u2010abl, mostly indicated for the treatment of patients with Philadelphia chromosome positive chronic myeloid leukaemia (CML). Generally, the undesirable effects of imatinib administration observed in clinical trials were of mild\u2010to\u2010moderate degree, and no haemolysis has been associated with this drug. We report here a case of immune\u2010mediated haemolytic anaemia associated to imatinib mesylate successfully treated with prednisone in a patient with CML. Laboratory investigation showed anaemia [haemoglobin (Hb) of 59\u2003g\/L], reticulocyte of 61\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/L and a positive direct antiglobulin test. Anti\u2010drug <jats:italic>in vitro<\/jats:italic> studies revealed a positive result with gel microcolumn assay by an adsorption mechanism. Seventy\u2010four days after prednisone therapy, the patient's Hb level was of 110\u2003g\/L with negative direct antiglobulin test and drug <jats:italic>in vitro<\/jats:italic> studies. This case demonstrated that patients treated with imatinib mesylate can present immune\u2010mediated haemolysis and adequate management of this event can be done maintaining the drug and associating corticosteroids.<\/jats:p>","DOI":"10.1046\/j.0902-4441.2003.00128.x","type":"journal-article","created":{"date-parts":[[2003,11,7]],"date-time":"2003-11-07T20:38:38Z","timestamp":1068237518000},"page":"455-458","source":"Crossref","is-referenced-by-count":16,"title":["First case of immune\u2010mediated haemolytic anaemia associated to imatinib mesylate"],"prefix":"10.1111","volume":"71","author":[{"given":"Marcia C.","family":"Zago Novaretti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme H. H.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f4nika","family":"Conchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Enrique","family":"Dorlhiac\u2010Llacer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalton","family":"de Alencar Fischer Chamone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,11,7]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06535-7"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200202283460919"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08616-6"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30290162894.x"},{"key":"e_1_2_8_8_2","first-page":"419","volume-title":"Technical Manual","author":"Vengelen\u2010Tyler V","year":"1999"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1992.32692367200.x"},{"key":"e_1_2_8_10_2","first-page":"115","article-title":"Drug\u2010induced hemolytic anemias: increasing complications to therapeutic interventions","volume":"12","author":"Wright MS.","year":"1999","journal-title":"Clin Lab Sci"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(93)70143-1"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1992.32392213800.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10281"},{"key":"e_1_2_8_14_2","first-page":"1208","volume-title":"Applied Blood Group Serology","author":"Issitt PD","year":"1998"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0902-4441.2003.00128.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.0902-4441.2003.00128.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.0902-4441.2003.00128.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:08:05Z","timestamp":1697216885000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.0902-4441.2003.00128.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,7]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1046\/j.0902-4441.2003.00128.x"],"URL":"https:\/\/doi.org\/10.1046\/j.0902-4441.2003.00128.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,7]]}}}